A Phase I trial evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of VIT-2763 on iron metabolism and blood levels when administered in single and multiple doses in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2018
At a glance
- Drugs VIT-2763 (Primary)
- Indications Iron overload
- Focus Adverse reactions; First in man
- 14 Feb 2018 New trial record
- 08 Feb 2018 According to a Vifor Pharma media release, this study will initiate at the beginning of March 2018 and first results from the study are expected in the second half of 2018.
- 19 Dec 2017 According to a Vifor Pharma media release, a Clinical Trial Application (CTA) for this trial was submitted in November 2017 and approved.